A Trial to Evaluate Pharmacokinetics Immunogenicity Safety and Tolerability of LEO 138559 in Healthy Japanese Subjects

  • STATUS
    Recruiting
  • End date
    Jul 12, 2022
  • participants needed
    24
  • sponsor
    LEO Pharma
Updated on 25 November 2021
body mass index
Accepts healthy volunteers

Summary

This trial will investigate the pharmacokinetics, immunogenicity, safety, and tolerability of LEO 138559 in healthy Japanese subjects.

The trial consists of a screening period of up to 4 weeks, a single treatment with either LEO 138559 or placebo, and 8 follow-up visits to Day 85.

A total of 24 healthy subjects will be enrolled in 3 dose groups (n=8 per dose group) and randomized to either LEO 138559 or placebo in a ratio of 6:2.

Details
Condition Dermatitis, Dermatitis, Atopic, Hand Dermatitis, Eczema (Atopic Dermatitis - Pediatric), ATOPIC DERMATITIS, Dermatite Atopique, Eczema (Atopic Dermatitis), Eczema, Atopic Dermatitis, Eczéma (Dermatite Atopique)
Treatment LEO 138559, LEO 138559 placebo
Clinical Study IdentifierNCT05099133
SponsorLEO Pharma
Last Modified on25 November 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Males and females between 18 to 65 years of age, inclusive, at the Screening visit
Japanese subjects to be considered ethnic Japanese must
Be born in Japan with parents and grandparents (maternal and paternal) of Japanese descent
Not have lived outside of Japan for more than 10 years at the time of Screening
No significant change in lifestyle since leaving Japan, including diet
Body mass index (BMI) between 18.0 and 32.0 kg/m2, inclusive, at the Screening visit
Healthy, determined by pre-trial medical evaluation at Principal Investigator's discretion

Exclusion Criteria

Female subjects of childbearing potential who are not willing to use highly effective contraception
Subject has clinically significant history or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, immunological, musculoskeletal, infectious, metabolic, hematologic, neurological, or psychiatric disorder(s) as determined by the Principal Investigator or designee
Subject has any surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of any drug as determined by the Principal Investigator or designee
Clinically significant infection within 4 weeks prior to randomization that may compromise the safety of the subject in the trial or the integrity of the trial. This includes clinically significant infections (common cold is allowed [with negative SARS-CoV-2 PCR test]) that in the opinion of the Investigator or Sponsor's Medical Monitor may compromise the safety of the subject in the trial, interfere with evaluation of the IMP, or reduce the subject's ability to participate in the trial
History of any active skin infection within 1 week prior to Screening or randomization
Subject who has taken immunosuppressive/immunomodulating medication within 4 weeks prior to randomization, topical corticosteroids, topical calcineurin inhibitors within 2 weeks prior to randomization, or was treated with biologics within 5 half-lives (if known) or 12 weeks prior to randomization, whichever is longer
Subject has used over-the-counter (OTC) medications (including vitamins), or herbal remedies from 14 days prior to admission until the End-of-trial Visit. By exception, paracetamol/acetaminophen 2 g per day is permitted
History of chronic alcohol or drug abuse within 12 months prior to Screening, or any condition associated with poor compliance as judged by the Investigator
Heavy smoker (daily average >10 cigarettes) within the last three months prior to Screening
Subject is unwilling to avoid use of alcohol or alcohol-containing foods, medications, or beverages, within 36 hours prior to admission until discharge from the Clinical Unit
Female subjects are breastfeeding or female subjects with a positive serum pregnancy test at the Screening visit or urine pregnancy test at admission
Subject is unwilling to avoid consumption of coffee and caffeine-containing beverages within 48 hours prior to admission until discharge from the Clinical Unit
Subject is unable to abstain from smoking (or other nicotine use) from admission until discharge from the Clinical Unit
Subject scheduled to receive COVID-19 vaccination within 2 weeks before IMP administration
Less than 4 weeks after the second COVID-19 vaccination or booster (if on a single dose vaccination, it should be 4 weeks after)
Live attenuated viral vaccine administration within 12 weeks before LEO 138559 or planned within three months after the last administration of LEO 138559
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note